Erasca, Inc. (NASDAQ:ERAS - Get Free Report)'s stock price gapped down prior to trading on Friday. The stock had previously closed at $14.22, but opened at $13.13. Erasca shares last traded at $13.9160, with a volume of 2,306,222 shares.
Key Headlines Impacting Erasca
These are some of the ERAS headlines that stood out recently:
- Positive Sentiment: ERAS-0015 showed confirmed tumor responses in advanced cancers: a 44% response rate in KRAS G12X pancreatic cancer, 69% in the G12D/G12V pancreatic subgroup, and 58% across dose levels in previously treated KRAS-mutant lung cancer. The results may strengthen the drug’s potential in difficult-to-treat tumors. Reuters article
- Neutral Sentiment: The company said ERAS-0015 was generally tolerated at the reported dose, and early combination findings and preliminary ERAS-4001 activity support further study. However, combination efficacy data remain limited or unavailable, and the reported response groups were small. RTTNews article
- Negative Sentiment: Despite the encouraging results, a report said early data left important questions unanswered, a possible reason shares came under pressure. The company also disclosed a prior treatment-related patient death from pneumonitis; although it reported no additional Grade 5 events, safety and efficacy will need validation in larger trials. Yahoo Finance article
Wall Street Analysts Forecast Growth
ERAS has been the topic of several recent research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Erasca in a research report on Tuesday, September 8th. Leerink Partners began coverage on shares of Erasca in a research note on Tuesday. They set an "outperform" rating and a $35.00 price target for the company. HC Wainwright upped their price objective on shares of Erasca from $18.00 to $22.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Guggenheim boosted their price objective on Erasca from $20.00 to $21.00 and gave the company a "buy" rating in a research note on Thursday, August 13th. Finally, Bank of America raised their price target on shares of Erasca from $18.00 to $20.00 and gave the company a "neutral" rating in a report on Friday, August 14th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.17.
Check Out Our Latest Report on ERAS
Erasca Trading Down 1.4%
The company's fifty day moving average is $14.81 and its 200 day moving average is $15.33. The company has a market cap of $4.92 billion, a P/E ratio of -14.12 and a beta of 0.68.
Erasca (NASDAQ:ERAS - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Analysts anticipate that Erasca, Inc. will post -0.51 EPS for the current year.
Institutional Trading of Erasca
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of Erasca in the 2nd quarter worth about $387,544,000. ARCH Venture Management LLC purchased a new stake in shares of Erasca in the 2nd quarter worth approximately $129,917,324. Janus Henderson Group PLC purchased a new position in shares of Erasca in the 1st quarter worth about $59,988,000. Assenagon Asset Management S.A. raised its holdings in Erasca by 407.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,128,332 shares of the company's stock worth $60,521,000 after acquiring an additional 3,315,456 shares during the last quarter. Finally, Commodore Capital LP bought a new position in shares of Erasca during the first quarter valued at $51,372,000. Hedge funds and other institutional investors own 67.78% of the company's stock.
About Erasca
(
Get Free Report)
Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company's pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Erasca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.
While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.